home / stock / lbtsf / lbtsf news


LBTSF News and Press, Almirall Sa Ord From 05/08/23

Stock Information

Company Name: Almirall Sa Ord
Stock Symbol: LBTSF
Market: OTC

Menu

LBTSF LBTSF Quote LBTSF Short LBTSF News LBTSF Articles LBTSF Message Board
Get LBTSF Alerts

News, Short Squeeze, Breakout and More Instantly...

LBTSF - Almirall's First Quarter 2023 Results

Almirall's Net Sales reach € 232MM and increase by 6%, boosted by a solid European dermatology business The European dermatology business achieved excellent performance, with Net Sales increasing by 11.4% year-on-year, driven by solid business momentum from key products and positiv...

LBTSF - Almirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis

Almirall S.A. (ALM) today announced results from a new secondary analysis from the Phase 3 clinical development program which showed patients receiving lebrikizumab who were assessed at 16 weeks experienced improved or cleared face or hand dermatitis, which can be particularly burdensome and ...

LBTSF - Almirall, S.A. (LBTSF) Q4 2022 Earnings Call Transcript

Almirall, S.A. (LBTSF) Q4 2022 Earnings Conference Call February 20, 2023, 04:00 AM ET Company Participants Pablo Divasson Fraile - Director of IR and Corporate Communications Carlos Gallardo - Chairman & Interim CEO Karl Ziegelbauer - Chief Scientific Officer ...

LBTSF - Almirall, S.A. reports FY results; initiates FY23 guidance

Almirall, S.A. press release ( OTCPK:LBTSF ): FY Revenue of €863.2M (+4.4% Y/Y). Total EBITDA reached €198.3M, a 15.8% Y/Y decrease. Almirall closed 2022 with a healthy balance sheet and solid liquidity position at 0.8x Net Debt to EBITDA. Core Gross Margin ...

LBTSF - Almirall's Full-Year 2022 Results

Almirall closes 2022 with a Core Net Sales growth of 6.6%, driven by its European Dermatology Business Almirall consolidates its position in Europe. The Dermatology business in this continent grew 18.4% year-on-year, boosted by new launches Almirall achieved its guidance for 202...

LBTSF - Almirall to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Carlos Gallardo, Chairman of Almirall, will represent the company in a session scheduled at 9am Pacific Standard Time on January 10 th , 2023 Almirall, S.A. (ALM) , a global biopharmaceutical company focused on skin health, today announced that it will participate in the u...

LBTSF - Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants

FACILITATE aims to create a framework for clinical trial participant’s data access and reutilisation for a fully transparent and ethical ecosystem Almirall brings its experience in privacy matters and pharmaceutical law, as well as in the development of guidance, ...

LBTSF - Almirall, S.A. (LBTSF) Q3 2022 Earnings Call Transcript

Almirall, S.A. (LBTSF) Q3 2022 Earnings Conference Call November 10, 2022 04:00 AM ET Company Participants Pablo Divasson del Fraile - Director of Investor Relations, Shareholders & ESG Carlos Gallardo - Chairman & Interim Chief Executive Officer Mike McC...

LBTSF - Almirall, S.A. 2022 Q3 - Results - Earnings Call Presentation

The following slide deck was published by Almirall, S.A. in conjunction with their 2022 Q3 earnings call. For further details see: Almirall, S.A. 2022 Q3 - Results - Earnings Call Presentation

LBTSF - Almirall, S.A. Non-GAAP EPS of Euro0.18, revenue of Euro633.8M

Almirall, S.A. press release ( OTCPK:LBTSF ): Q3 Non-GAAP EPS of €0.18. Revenue of €633.8M (+5.3% Y/Y). For further details see: Almirall, S.A. Non-GAAP EPS of €0.18, revenue of €633.8M

Previous 10 Next 10